BioPorto A/S (THOXF)
OTCMKTS · Delayed Price · Currency is USD
0.2880
+0.0580 (25.22%)
At close: Jun 26, 2024
BioPorto Revenue
BioPorto had revenue of 10.59M DKK in the quarter ending June 30, 2025, with 15.12% growth. This brings the company's revenue in the last twelve months to 35.84M, up 5.94% year-over-year. In the year 2024, BioPorto had annual revenue of 36.24M with 17.07% growth.
Revenue (ttm)
35.84M DKK
Revenue Growth
+5.94%
P/S Ratio
16.11
Revenue / Employee
746.67K DKK
Employees
48
Market Cap
90.92M USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
BioPorto News
- 4 weeks ago - BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented - GlobeNewsWire
- 2 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 2 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga
- 3 months ago - BioPorto A/S to host an investor webcast on the results for the first half of 2025 - GlobeNewsWire
- 3 months ago - BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. - GlobeNewsWire
- 4 months ago - BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy - GlobeNewsWire
- 6 months ago - BioPorto A/S to host first quarter 2025 earnings webcast for investors - GlobeNewsWire
- 6 months ago - BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million - GlobeNewsWire